page_title: Intas Biopharmaceuticals
section_title: History
hierarchical_section_title: Intas Biopharmaceuticals / History
caption_attribution_description: English: Corporate and Manufacturing Site of Intas biopharmaceuticals Ltd.
context_page_description: The Biologics Business Unit of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as Intas Biopharmaceuticals Ltd. Intas Pharmaceuticals limited is an Indian company headquartered in Ahmedabad, India. The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading biosimilar product manufacturers in Asia.
  The Biologics BU of Intas Pharmaceuticals has biopharmaceutical operations with R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.
context_section_description: Intas Biopharmaceuticals Limited was set up in 1980 by Dr Urmish Chudgar, a leading hematooncologist, as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Mr. Hasmukh Chudgar.
  The company faced an EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the  first company in India to receive such certification.
  Apart from EU-GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.
  In 2015, the company launched Accofil, a treatment for immune system disorders. In 2016, Intas acquired the assets of Teva Pharmaceuticals in the UK and Ireland for $764 million.
  In 2017, the company announced acquisition of Actavis UK Ltd. & Actavis Ireland Ltd from Teva Pharmaceutical Industries Ltd, for an enterprise value of GBP 603 million.
caption: Corporate headquarters and production site of Intas Biopharmaceuticals Ltd.
exif: {"Image ImageDescription": "Stitched Panorama", "Image Make": "Canon", "Image Model": "Canon IXY DIGITAL 800 IS", "Image Orientation": "Horizontal (normal)", "Image XResolution": "72", "Image YResolution": "72", "Image ResolutionUnit": "Pixels/Inch", "Image Software": "Adobe Photoshop CS3 Windows", "Image DateTime": "2008:06:12 18:15:14", "Image YCbCrPositioning": "Centered", "Image CustomRendered": "Normal", "Image ExposureMode": "Manual Exposure", "Image WhiteBalance": "Auto", "Image DigitalZoomRatio": "1", "Image SceneCaptureType": "Standard", "Image Padding": "[]", "Image ExifOffset": "2400", "Thumbnail Compression": "JPEG (old-style)", "Thumbnail XResolution": "72", "Thumbnail YResolution": "72", "Thumbnail ResolutionUnit": "Pixels/Inch", "Thumbnail JPEGInterchangeFormat": "3030", "Thumbnail JPEGInterchangeFormatLength": "3733", "EXIF ExposureTime": "1/200", "EXIF FNumber": "28/5", "EXIF ExifVersion": "0220", "EXIF DateTimeOriginal": "2008:05:28 18:16:26", "EXIF DateTimeDigitized": "2008:05:28 18:16:26", "EXIF ComponentsConfiguration": "YCbCr", "EXIF CompressedBitsPerPixel": "5", "EXIF ShutterSpeedValue": "245/32", "EXIF ApertureValue": "159/32", "EXIF ExposureBiasValue": "1", "EXIF MaxApertureValue": "95/32", "EXIF MeteringMode": "Pattern", "EXIF Flash": "Flash did not fire, compulsory flash mode", "EXIF FocalLength": "29/5", "EXIF FlashPixVersion": "0100", "EXIF ColorSpace": "sRGB", "EXIF ExifImageWidth": "542", "EXIF ExifImageLength": "258", "EXIF FocalPlaneXResolution": "90880/9", "EXIF FocalPlaneYResolution": "1704000/169", "EXIF FocalPlaneResolutionUnit": "2", "EXIF SensingMethod": "One-chip color area", "EXIF FileSource": "Digital Camera"}